Well Referenced

Tag: Viscum album

Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research

This systematic review evaluated the clinical and preclinical effects of Viscum album L. (European mistletoe) extracts (VAE) in breast and gynaecological cancers. It included 19 randomized controlled trials (RCTs), 16 non-randomized controlled studies, and 11 single-arm cohort studies, encompassing over 9,900 patients. Findings indicated that VAE may improve quality of

Read More »
June 26, 2025 No Comments

Prospective Controlled Cohort Studies on Long-Term Therapy of Ovarian Cancer Patients with Mistletoe (Viscum album L.) Extracts Iscador

This 2007 study assessed the impact of long-term Iscador therapy on survival and psychosomatic self-regulation in ovarian cancer patients. It included two randomized matched-pair studies and two non-randomized matched-pair studies, comparing patients receiving Iscador with controls. Results indicated that Iscador therapy might prolong overall survival, particularly in patients with distant

Read More »
June 26, 2025 No Comments

Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study

This large-scale observational study evaluated the safety of intravenous mistletoe preparations (Helixor, Abnoba viscum, Iscador) in 475 oncology patients. Over 4,500 infusions were analyzed. Adverse drug reactions (ADRs) were reported in 4.6% of patients, with 59.4% of these being mild and 40.6% moderate; no severe ADRs were observed. ADRs occurred

Read More »
June 26, 2025 No Comments

Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer

This phase I dose-escalation trial investigated the safety and tolerability of intravenous mistletoe extract (Helixor® P) in 21 patients with advanced, treatment-resistant malignancies. Doses ranged from 200 to 2000 mg weekly over a 3-week period, with a 9-week extension for high-dose patients. The maximum tolerated dose was not reached. One

Read More »
June 26, 2025 No Comments

The Case for Mistletoe in the Treatment of Laryngeal Cancer

This 2014 case report details a 68-year-old patient with aggressive, non-resectable laryngeal carcinoma who achieved complete remission following mistletoe therapy after failing to respond to chemoradiotherapy and salvage laryngectomy. The patient received high-dose intratumoral applications of Viscum album extract (mistletoe), leading to full recovery and hospital discharge. The report underscores

Read More »
June 26, 2025 No Comments

The Influence of Isorel on Advanced Colorectal Cancer

This 2003 randomized, controlled clinical study investigated the impact of Isorel, a mistletoe extract (Viscum album L.), as an adjunct therapy in patients with advanced colorectal cancer (Dukes C and D stages). Participants were allocated into three groups: surgery alone, surgery plus standard 5-fluorouracil (5-FU) chemotherapy, and surgery plus chemotherapy

Read More »
June 26, 2025 No Comments

Influence of Complementary Viscum album (Iscador) Administration on Microcirculation and Immune System of Ear, Nose and Throat Carcinoma Patients Treated with Radiation and Chemotherapy

This 2005 clinical trial investigated the effects of adjunctive Viscum album extract (Iscador) therapy on microcirculation and immune function in patients with ear, nose, and throat carcinomas undergoing radiotherapy and chemotherapy. Using vital microscopic and reflection spectrometric imaging, the study assessed microcirculatory parameters and white blood cell immunology before, during,

Read More »
June 26, 2025 No Comments

High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series

This 2015 retrospective case series evaluated the potential of high-dose Viscum album (European mistletoe) extract therapy in preventing bladder cancer recurrence. Eight patients with resectable bladder cancer (7 non-muscle-invasive, 1 muscle-invasive) received subcutaneous injections of high-dose Viscum album extract between 2006 and 2012. Prior to this therapy, patients had experienced

Read More »
June 26, 2025 No Comments